Press Releases Roche Holding AG Börse Stuttgart

Equities

RHO

CH0012032113

Delayed Börse Stuttgart Other stock markets 09:43:21 2019-06-28 EDT			5-day change	1st Jan Change
245 ^EUR	-0.08%		-2.62%	+15.68%

06:26pm	ROCHE HOLDING : Obesity could lead Roche’s redemption journey
06:24pm	Global markets live: Adidas, TSMC, Vale, HSBC, J&J...

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study	11:46am	BU
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity	01:11am	BU
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)	07-08	BU
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss	07-05	BU
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer	07-04	BU
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	06-15	BU
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk	06-07	BU
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	05-29	BU
Roche and Hitachi High-Tech extend their long-standing partnership	05-28	AQ
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation	05-21	BU
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity	05-16	BU
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	04-18	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	04-17	BU
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	04-15	BU
Invitation to Roche's First Quarter Sales 2024 Presentation	03-25	AQ
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024	03-12	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	03-06	AQ
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	02-25	BU
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	02-19	AQ
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	02-16	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am